For a clinical implication, the synergism demonstrated in this study supports the rationale to further investigate the combination of PARP and ATR inhibitors in HRR-deficient cells beyond BRCA1/2 that may give advantages for cancer patients without germline mutations in BRCA1/2. This evidence concerns the gene BRCA1 and cancer.